Advertisement

Lactobacillus plantarum PS128 Ameliorated Visceral Hypersensitivity in Rats Through the Gut–Brain Axis

  • Yen-Wenn Liu
  • Yen-Po Wang
  • Hsu-Fang Yen
  • Pei-Yi Liu
  • Wen-Jian Tzeng
  • Chia-Fen Tsai
  • Han-Chieh Lin
  • Fa-Yauh Lee
  • One-Jang Jeng
  • Ching-Liang LuEmail author
  • Ying-Chieh TsaiEmail author
Article

Abstract

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain and alterations in bowel habits. Current treatments for IBS are unsatisfactory due to its multifactorial pathogenesis involving the microbiota–gut–brain axis. Lactobacillus plantarum PS128 (PS128) was reported to exhibit neuromodulatory activity which may be beneficial for improving IBS. This study aimed to investigate the effect of PS128 on visceral hypersensitivity (VH) and the gut–brain axis using a 5-hydroxytryptophan (5-HTP)-induced VH rat model without colonic inflammation induction, mimicking the characteristics of IBS. Male Sprague–Dawley rats were administered with PS128 (109 CFU in 0.2 mL saline/rat/day) or saline (0.2 mL saline/rat/day) for 14 days. Colorectal distension (CRD) with simultaneous electromyography recording was performed 30 min before and 30 min after the 5-HTP injection. Levels of neuropeptides and neurotrophins were analyzed. PS128 significantly reduced VH induced by the 5-HTP injection and CRD. Neurotransmitter protein levels, substance P, CGRP, BDNF, and NGF, were decreased in the dorsal root ganglion but increased in the spinal cord in response to the 5-HTP injection; PS128 reversed these changes. The hypothalamic–pituitary–adrenal axis was modulated by PS128 with decreased corticosterone concentration in serum and the expression of mineralocorticoid receptors in the amygdala. Oral administration of PS128 inhibited 5-HTP-induced VH during CRD. The ameliorative effect on VH suggests the potential application of PS128 for IBS.

Keywords

Irritable bowel syndrome (IBS) Lactobacillus plantarum PS128 (PS128) Visceral hypersensitivity (VH) 5-Hydroxytryptophan (5-HTP) Psychobiotics 

Notes

Funding Information

This research was financially supported by grants from Academic Technology Development Program of the Ministry of Economic Affairs, Republic of China (101-EC-17-A-17-S1-197; 102-EC-17-A-17-S1-197; 103-EC-17-A-17-S1-197), Ministry of Science and Technology, Republic of China (MOST-102-2313-B-010-001-MY3; MOST 107-2320-B-010-003-MY2), National Science Council (NSC 101-2314-B-010-053), and Taipei Veterans General Hospital (V104E13-001-MY2-1).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Supplementary material

12602_2019_9595_MOESM1_ESM.pdf (135 kb)
ESM 1 (PDF 135 kb)

References

  1. 1.
    Chang FY, Lu CL, Chen TS (2010) The current prevalence of irritable bowel syndrome in Asia. J Neurogastroenterol Motil 16:389–400PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Quigley EM, Abdel-Hamid H, Barbara G, Bhatia SJ, Boeckxstaens G, De Giorgio R, Delvaux M, Drossman DA, Foxx-Orenstein AE, Guarner F, Gwee KA, Harris LA, Hungin AP, Hunt RH, Kellow JE, Khalif IL, Kruis W, Lindberg G, Olano C, Moraes-Filho JP, Schiller LR, Schmulson M, Simren M, Tzeuton C (2012) A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 46:356–366PubMedCrossRefGoogle Scholar
  3. 3.
    Grundmann O, Yoon SL (2010) Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 25:691–699PubMedCrossRefGoogle Scholar
  4. 4.
    Lu CL, Chen CY, Lang HC, Luo JC, Wang SS, Chang FY, Lee SD (2003) Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. Aliment Pharmacol Ther 18:1159–1169PubMedCrossRefGoogle Scholar
  5. 5.
    Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R (2016) Bowel Disorders. Gastroenterology 150:1393–1407CrossRefGoogle Scholar
  6. 6.
    Chey WD, Kurlander J, Eswaran S (2015) Irritable bowel syndrome: a clinical review. JAMA 313:949–958PubMedCrossRefGoogle Scholar
  7. 7.
    Fayyaz M, Lackner JM (2008) Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther Clin Risk Manag 4:41–48PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P (2009) Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 104:1831–1843PubMedCrossRefGoogle Scholar
  9. 9.
    Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P (2014) Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 109:1350–1365PubMedCrossRefGoogle Scholar
  10. 10.
    Chang L, Lembo A, Sultan S (2014) American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology 147:1149–1172PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107:1702–1712PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Jeffery IB, O’Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, Simren M (2012) An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61:997–1006PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141:1792–1801PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Rajilic-Stojanovic M, Jonkers DM, Salonen A, Hanevik K, Raes J, Jalanka J, de Vos WM, Manichanh C, Golic N, Enck P, Philippou E, Iraqi FA, Clarke G, Spiller RC, Penders J (2015) Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 110:278–287PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Menees SB, Maneerattannaporn M, Kim HM, Chey WD (2012) The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 107:28–35PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Verdu EF, Bercik P, Bergonzelli GE, Huang XX, Blennerhasset P, Rochat F, Fiaux M, Mansourian R, Corthesy-Theulaz I, Collins SM (2004) Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 127:826–837PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Johnson AC, Greenwood-Van Meerveld B, McRorie J (2011) Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat. Dig Dis Sci 56:3179–3186PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Ait-Belgnaoui A, Han W, Lamine F, Eutamene H, Fioramonti J, Bueno L, Theodorou V (2006) Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 55:1090–1094PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A (2012) Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J Gastroenterol 18:2067–2075PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Theodorou V, Ait Belgnaoui A, Agostini S, Eutamene H (2014) Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome. Gut Microbes 5:430–436PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P (2014) Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109:1547–1561PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Chao SH, Wu RJ, Watanabe K, Tsai YC (2009) Diversity of lactic acid bacteria in suan-tsai and fu-tsai, traditional fermented mustard products of Taiwan. Int J Food Microbiol 135:203–210PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Liu WH, Chuang HL, Huang YT, Wu CC, Chou GT, Wang S, Tsai YC (2016) Alteration of behavior and monoamine levels attributable to Lactobacillus plantarum PS128 in germ-free mice. Behav Brain Res 298:202–209PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Liu YW, Liu WH, Wu CC, Juan YC, Wu YC, Tsai HP, Wang S, Tsai YC (2016) Psychotropic effects of Lactobacillus plantarum PS128 in early life-stressed and naive adult mice. Brain Res 1631:1–12PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Liu WH, Yang CH, Lin CT, Li SW, Cheng WS, Jiang YP, Wu CC, Chang CH, Tsai YC (2015) Genome architecture of Lactobacillus plantarum PS128, a probiotic strain with potential immunomodulatory activity. Gut Pathogens 7:22PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Lu CL, Hsieh JC, Tsaur ML, Huang YH, Wang PS, Wu LL, Liu PY, Chang FY, Lee SD (2007) Estrogen rapidly modulates mustard oil-induced visceral hypersensitivity in conscious female rats: a role of CREB phosphorylation in spinal dorsal horn neurons. Am J Physiol Gastrointest Liver Physiol 292:G438–G446PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Lu CL, Hsieh JC, Dun NJ, Oprea TI, Wang PS, Luo JC, Lin HC, Chang FY, Lee SD (2009) Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hypersensitivity via GPR30 in rats. Gastroenterology 137:1040–1050PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Banner SE, Sanger GJ (1995) Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol 114:558–562PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Paxinos G (1998) The rat brain in stereotaxic coordinates. Elsevier Academic PressGoogle Scholar
  31. 31.
    Liou YJ, Chen CH, Cheng CY, Chen SY, Chen TJ, Yu YWY, Nian FS, Tsai SJ, Hong CJ (2012) Convergent evidence from mouse and human studies suggests the involvement of zinc finger protein 326 gene in antidepressant treatment response. PLoS One 7:e32984PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Meldgaard M, Fenger C, Lambertsen KL, Pedersen MD, Ladeby R, Finsen B (2006) Validation of two reference genes for mRNA level studies of murine disease models in neurobiology. J Neurosci Methods 156:101–110PubMedCrossRefGoogle Scholar
  33. 33.
    Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ (2013) Probiotics and irritable bowel syndrome. World J Gastroenterol 19:5973–5980PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Didari T, Mozaffari S, Nikfar S, Abdollahi M (2015) Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol 21:3072–3084PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M (2008) Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 51:1775–1780PubMedCrossRefGoogle Scholar
  36. 36.
    Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P (2018) Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 48:1044–1060PubMedCrossRefGoogle Scholar
  37. 37.
    Whitehead WE, Palsson O, Jones KR (2002) Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 122:1140–1156PubMedCrossRefGoogle Scholar
  38. 38.
    Ladabaum U, Boyd E, Zhao WK, Mannalithara A, Sharabidze A, Singh G, Chung E, Levin TR (2012) Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol 10:37–45PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS (2016) Short-term and long-term efficacy of psychological therapies for irritable bowel syndrome: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 14:937–947PubMedCrossRefGoogle Scholar
  40. 40.
    Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG (2010) Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience 170:1179–1188CrossRefGoogle Scholar
  41. 41.
    McKernan DP, Fitzgerald P, Dinan TG, Cryan JF (2010) The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil 22:1029–1035PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101:1581–1590PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Lu CL, Chang FY, Lang HC, Chen CY, Luo JC, Lee SD (2005) Gender difference on the symptoms, health-seeking behaviour, social impact and sleep quality in irritable bowel syndrome: a Rome II-based survey in an apparent healthy adult Chinese population in Taiwan. Aliment Pharmacol Ther 21:1497–1505PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Gschossmann JM, Coutinho SV, Miller JC, Huebel K, Naliboff B, Wong HC, Walsh JH, Mayer EA (2001) Involvement of spinal calcitonin gene-related peptide in the development of acute visceral hyperalgesia in the rat. Neurogastroenterol Motil 13:229–236PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Wang WF, Yang YS, Peng LH, Sun G (2006) Alternation of substance P-containing neural pathways in a rat model of irritable bowel syndrome with rectal distension. Chin J Dig Dis 7:211–218PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Winston JH, Li Q, Sarna SK (2014) Chronic prenatal stress epigenetically modifies spinal cord BDNF expression to induce sex-specific visceral hypersensitivity in offspring. Neurogastroenterol Motil 26:715–730PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM (2006) Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 27:85–91PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Thompson SW, Bennett DL, Kerr BJ, Bradbury EJ, McMahon SB (1999) Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proc Natl Acad Sci U S A 96:7714–7718PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Delafoy L, Raymond F, Doherty AM, Eschalier A, Diop L (2003) Role of nerve growth factor in the trinitrobenzene sulfonic acid-induced colonic hypersensitivity. Pain 105:489–497PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Delafoy L, Gelot A, Ardid D, Eschalier A, Bertrand C, Doherty AM, Diop L (2006) Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat. Gut 55:940–945PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Qiao LY, Grider JR (2009) Colitis induces calcitonin gene-related peptide expression and Akt activation in rat primary afferent pathways. Exp Neurol 219:93–103PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Gibney SM, Gosselin RD, Dinan TG, Cryan JF (2010) Colorectal distension-induced prefrontal cortex activation in the Wistar-Kyoto rat: implications for irritable bowel syndrome. Neuroscience 165:675–683PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Gao J, Wu X, Owyang C, Li Y (2006) Enhanced responses of the anterior cingulate cortex neurones to colonic distension in viscerally hypersensitive rats. J Physiol 570:169–183PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L (2005) Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 115:398–409PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Price DD (2000) Psychological and neural mechanisms of the affective dimension of pain. Science 288:1769–1772PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Keszthelyi D, Troost FJ, Jonkers DM, van Eijk HM, Dekker J, Buurman WA, Masclee AA (2015) Visceral hypersensitivity in irritable bowel syndrome: evidence for involvement of serotonin metabolism--a preliminary study. Neurogastroenterol Motil 27:1127–1137PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Garabadu D, Shah A, Singh S, Krishnamurthy S (2015) Protective effect of eugenol against restraint stress-induced gastrointestinal dysfunction: potential use in irritable bowel syndrome. Pharm Biol 53:968–974PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Myers B, Greenwood-Van Meerveld B (2010) Divergent effects of amygdala glucocorticoid and mineralocorticoid receptors in the regulation of visceral and somatic pain. Am J Physiol Gastrointest Liver Physiol 298:G295–G303PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Myers B, Dittmeyer K, Greenwood-Van Meerveld B (2007) Involvement of amygdaloid corticosterone in altered visceral and somatic sensation. Behav Brain Res 181:163–167PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Reul JM, de Kloet ER (1985) Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 117:2505–2511PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Johnson AC, Tran L, Schulkin J, Greenwood-Van Meerveld B (2012) Importance of stress receptor-mediated mechanisms in the amygdala on visceral pain perception in an intrinsically anxious rat. Neurogastroenterol Motil 24:479–486PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Myers B, Greenwood-Van Meerveld B (2007) Corticosteroid receptor-mediated mechanisms in the amygdala regulate anxiety and colonic sensitivity. Am J Physiol Gastrointest Liver Physiol 292:G1622–G1629PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Chang L, Sundaresh S, Elliott J, Anton PA, Baldi P, Licudine A, Mayer M, Vuong T, Hirano M, Naliboff BD, Ameen VZ, Mayer EA (2009) Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil 21:149–159PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Dinan TG, Quigley EM, Ahmed SM, Scully P, O’Brien S, O’Mahony L, O’Mahony S, Shanahan F, Keeling PW (2006) Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 130:304–311PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Wilder-Smith CH, Schindler D, Lovblad K, Redmond SM, Nirkko A (2004) Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 53:1595–1601PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Biochemistry and Molecular BiologyNational Yang-Ming UniversityTaipeiTaiwan
  2. 2.Microbiome Research CenterNational Yang-Ming UniversityTaipeiTaiwan
  3. 3.Endoscopy Center for Diagnosis and TreatmentTaipei Veterans General HospitalTaipeiTaiwan
  4. 4.Institute of Brain ScienceNational Yang-Ming UniversityTaipeiTaiwan
  5. 5.School of MedicineNational Yang-Ming UniversityTaipeiTaiwan
  6. 6.Department of PsychiatryTaipei Veterans General HospitalTaipeiTaiwan
  7. 7.Division of GastroenterologyTaipei Veterans General HospitalTaipeiTaiwan
  8. 8.Bened Biomedical Co., Ltd.TaipeiTaiwan

Personalised recommendations